UNSPSC 51183501: Benfosformin

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 49030P3C8S. European Medicines Agency schedules Benfosformin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05715MIG. Benfosformin generally arises in the molecular formula C9H12N5O3P.2NA.H2O.

UNSPSC 51183501 Benfosformin is a Commodity code representing pharmaceutical active ingredients and finished-form drugs that state and local health systems, correctional facilities, and public health agencies procure for patient care and institutional use. The code's scope encompasses branded and generic pharmaceutical products distributed through established wholesaler networks, including the multi-source generic pharmaceuticals and over-the-counter products now being solicited across state and local government facilities nationwide.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 to establish multiple contracts for generic pharmaceuticals and OTC products (Solicitation S1070000015802, due March 26, 2026). The procurement serves participating state and local government facilities, including Oregon, and requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of the three authorized wholesalers with chargeback systems in place, and submit detailed product information including National Drug Codes, SKUs, UPCs, strength, dosage form, and packaging configurations. Evaluation emphasizes price competitiveness (75 percent weight), with additional scoring on fixed pricing for the contract term (10 percent), EDI capability (5 percent), compliance with administrative fee data format requirements (5 percent), and agreement to a 3 percent administrative fee (5 percent). The contract term is two years for new responders with optional MMCAP extensions; awarded vendors will be effective July 1, 2026. All products must be available in the marketplace by May 15, 2026 and comply with FDA requirements with expiration dates at least one year from manufacture.